Atazanavir Sulfate. Fresh from the Pipeline
Nature Reviews Drug Discovery
In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?
Raja, Aarti; J. Lebbos; and P. Kirkpatrick. 2003. "Atazanavir Sulfate. Fresh from the Pipeline." Nature Reviews Drug Discovery , (). https://nsuworks.nova.edu/cnso_bio_facarticles/69